Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use Extension of Ublituximab + Umbralisib in CLL Patients from UTX-TGR-304
2016-004339-19Phase 2Terminated
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ublituximab and umbralisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by TG Therapeutics, Inc. Primary endpoint: Overall response rate. Started Jan 2017; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2016-004339-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004339-19.